UK NICE Releases Second Positive MedTech Innovation Briefing for AlignRT

23 August 2018. The UK National Institute for Health and Care Excellence (NICE) today released a MedTech Innovation Briefing (MIB) on AlignRT for breast cancer radiotherapy treatment. AlignRT is Vision RT’s market-leading solution for Surface Guided Radiation Therapy (SGRT).

This briefing summarised the evidence for the use of AlignRT in this indication, stating that “The innovative aspect is that it may avoid inaccurate treatment by precisely tracking a patient’s position during radiotherapy and notifying the linear accelerator to hold the radiation beam if the patient moves.”

MIBs are NICE advice. They are designed to support NHS and social care commissioners and staff who are considering using new medical devices and other medical or diagnostic technologies.

Thomas Carter, Senior Director of Global Marketing at Vision RT, stated “NICE use rigorous processes to assess new technology and are a key part of the adoption of clinical and health economic best practice, not only in the UK but also elsewhere in the world. We are very encouraged by this Medtech Innovation Briefing which covers an application for which hundreds of Vision RT SGRT systems have been deployed to leading cancer centres worldwide.”

“AlignRT is already used in the UK for breast cancer, intracranial stereotactic radiosurgery, as well as other conditions, where patients may benefit not only from the accuracy of the product but also avoiding the need for radiotherapy tattoos.”

Please click here for the NICE document.